Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
March 12 2021 - 10:10AM
Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced the
closing of its previously announced underwritten public offering of
5,750,000 shares of its common stock at a public offering price of
$11.25 per share, including 750,000 shares sold pursuant to the
full exercise of the underwriters’ option to purchase additional
shares. Gross proceeds from the sale of the shares, before
deducting underwriting discounts and commissions and offering
expenses, were approximately $64.7 million.
Cowen and Piper Sandler acted as joint
book-running managers for the offering.
The shares were offered by Jounce pursuant to a
shelf registration statement that was filed with the Securities and
Exchange Commission (“SEC”) on March 8, 2018 and declared effective
by the SEC on May 1, 2018. The offering was made solely by means of
a prospectus supplement and accompanying prospectus that form a
part of the registration statement. A final prospectus supplement
relating to, and describing the terms of, the offering has been
filed with the SEC and is available on the SEC’s web site at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering can be obtained
from Cowen and Company, LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at 833-297-2926; or from Piper Sandler
& Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Jounce TherapeuticsJounce
Therapeutics, Inc. is a clinical-stage immunotherapy company
dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and
provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce currently has multiple
development stage programs ongoing while simultaneously advancing
additional early-stage assets from its robust discovery engine
based on its Translational Science Platform. Jounce’s highest
priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist
shown to reprogram immune-suppressive tumor associated macrophages
to an anti-tumor state in preclinical studies. A Phase 1 clinical
trial, named INNATE, for JTX-8064 as a monotherapy and in
combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or
pembrolizumab is currently enrolling patients with advanced solid
tumors. Jounce’s most advanced product candidate, vopratelimab, is
a monoclonal antibody that binds to and activates ICOS, and is
currently being studied in the SELECT Phase 2 trial. JTX-4014 is a
PD-1 inhibitor intended for combination use in the INNATE and
SELECT trials and with Jounce’s broader pipeline. Additionally,
Jounce exclusively licensed worldwide rights to JTX-1811, a
monoclonal antibody targeting CCR8 and designed to selectively
deplete T regulatory cells in the tumor microenvironment, to Gilead
Sciences, Inc.
Investor and Media
Contacts:Malin DeonJounce Therapeutics,
Inc.+1-857-259-3843mdeon@jouncetx.com
Mark YoreJounce Therapeutics,
Inc.+1-857-200-1255 myore@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024